What is HC Wainwright’s Estimate for ARQT Q3 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Arcutis Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $0.17 per share for the quarter, up from their prior forecast of $0.06. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.44 EPS, FY2027 earnings at $1.00 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $2.07 EPS and FY2030 earnings at $2.36 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The firm had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%.

Several other research analysts also recently commented on ARQT. Morgan Stanley raised their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings upgraded Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Guggenheim lifted their price target on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Finally, Needham & Company LLC upped their price target on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Arcutis Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.57.

Arcutis Biotherapeutics Stock Performance

NASDAQ:ARQT opened at $25.92 on Monday. The stock has a 50-day simple moving average of $26.14 and a two-hundred day simple moving average of $24.69. Arcutis Biotherapeutics has a 52-week low of $14.03 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The firm has a market capitalization of $3.26 billion, a PE ratio of 123.43 and a beta of 1.49.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Hedge funds have recently modified their holdings of the stock. Focus Partners Wealth grew its stake in shares of Arcutis Biotherapeutics by 0.8% in the 3rd quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after buying an additional 490 shares in the last quarter. Schroder Investment Management Group raised its position in shares of Arcutis Biotherapeutics by 1.1% during the 4th quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock valued at $1,604,000 after buying an additional 594 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Arcutis Biotherapeutics by 124.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after buying an additional 698 shares in the last quarter. Entropy Technologies LP lifted its holdings in shares of Arcutis Biotherapeutics by 7.0% in the 4th quarter. Entropy Technologies LP now owns 12,144 shares of the company’s stock valued at $353,000 after acquiring an additional 792 shares during the last quarter. Finally, DNB Asset Management AS lifted its holdings in shares of Arcutis Biotherapeutics by 3.0% in the 4th quarter. DNB Asset Management AS now owns 27,786 shares of the company’s stock valued at $807,000 after acquiring an additional 802 shares during the last quarter.

Insiders Place Their Bets

In other Arcutis Biotherapeutics news, Director Sue-Jean Lin sold 4,946 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.38, for a total value of $120,583.48. Following the completion of the transaction, the director directly owned 27,567 shares in the company, valued at $672,083.46. This represents a 15.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Howard G. Welgus sold 4,096 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.41, for a total transaction of $99,983.36. Following the sale, the director directly owned 38,378 shares of the company’s stock, valued at approximately $936,806.98. This trade represents a 9.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 16,237 shares of company stock worth $408,214 over the last quarter. Company insiders own 9.40% of the company’s stock.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.